Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RORC | P51449 | 1/20 | 0.32 |
| ▸ | KCNH2 | Q12809 | 4/20 | 0.32 |
| ▸ | TUBB4A | P04350 | 3/20 | 0.31 |
| ▸ | TUBB | P07437 | 3/20 | 0.31 |
| ▸ | TUBA3C | P0DPH7 | 3/20 | 0.31 |
| ▸ | TUBA1B | P68363 | 3/20 | 0.31 |
| ▸ | TUBA4A | P68366 | 3/20 | 0.31 |
| ▸ | TUBB4B | P68371 | 3/20 | 0.31 |
| ▸ | TUBB3 | Q13509 | 3/20 | 0.31 |
| ▸ | TUBB2A | Q13885 | 3/20 | 0.31 |
| ▸ | TUBB8 | Q3ZCM7 | 3/20 | 0.31 |
| ▸ | TUBA3E | Q6PEY2 | 3/20 | 0.31 |
| ▸ | TUBA1A | Q71U36 | 3/20 | 0.31 |
| ▸ | TUBA1C | Q9BQE3 | 3/20 | 0.31 |
| ▸ | TUBB6 | Q9BUF5 | 3/20 | 0.31 |
| ▸ | TUBB2B | Q9BVA1 | 3/20 | 0.31 |
| ▸ | TUBB1 | Q9H4B7 | 3/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.31 |
| ▸ | TP53 | P04637 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17275595 | 0.80 | RAPGEF4 (0.45) | KDM4EHPGDHSD17B10SMN1; SMN2RAPGEF4 | |
| SCHEMBL1856356 | 0.76 | KDM4E (0.46) | TUBB4ATUBBTUBA3CTUBA1BTUBA4A | |
| SCHEMBL1860633 | 0.75 | CACNA1H (0.36) | RORCALDH1A1KDM4EHPGDHSD17B10 | |
| SCHEMBL2502244 | 0.70 | KDM4E (0.36) | ALDH1A1KDM4ESMN1; SMN2MEN1GAA | |
| SCHEMBL28979 | 0.69 | HTR2A (0.49) | ALDH1A1KDM4EMEN1MAPTKMT2A | |
| SCHEMBL3035285 | 0.68 | AKR1C3 (0.39) | ALDH1A1HPGDHDAC8SMN1; SMN2MEN1 | |
| SCHEMBL5154395 | 0.68 | KDM4E (0.35) | ALDH1A1KDM4EHDAC11HDAC8HDAC6 | |
| SCHEMBL413823 | 0.68 | HTR2A (0.50) | — | |
| SCHEMBL30967900 | 0.68 | HTR2A (0.50) | — | |
| SCHEMBL3327014 | 0.68 | MAPT (0.33) | MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8163729-B2 | Modulators of α7 nicotinic acetylcholine receptors and therapeutic uses thereof | WYETH (US) | 2012-04-24 | — | — | US | disclosed |
| EP-2323988-A1 | ALPHA7 NICOTINIC ACETYLCHOLINE RECEPTOR INHIBITORS | Wyeth LLC (US) | 2011-05-25 | — | — | EP | disclosed |
| US-20100130474-A1 | ALPHA7 NICOTINIC ACETYLCHOLINE RECEPTOR INHIBITORS | WYETH (US) | 2010-05-27 | — | — | US | disclosed |
| US-20100029606-A1 | MODULATORS OF ALPHA7 NICOTINIC ACETYLCHOLINE RECEPTORS AND THERAPEUTIC USES THEREOF | WYETH (US) | 2010-02-04 | — | — | US | disclosed |
| WO-2010009290-A1 | ALPHA7 NICOTINIC ACETYLCHOLINE RECEPTOR INHIBITORS | WYETH (US) | 2010-01-21 | — | — | WO | disclosed |
| EP-2118067-A1 | NICOTINIC ACETYLCHOLINE RECEPTOR MODULATORS | Siena Biotech S.p.A. (IT) | 2009-11-18 | — | — | EP | disclosed |
| CN-101374810-A | Modulators of alpha7 nicotinic acetylcholine receptors and therapeutic uses thereof | SIENA BIOTECH SPA (IT) | 2009-02-25 | — | — | CN | disclosed |
| EP-1991528-A2 | MODULATORS OF ALPHA7 NICOTINIC ACETYLCHOLINE RECEPTORS AND THERAPEUTIC USES THEREOF | Siena Biotech S.p.A. (IT) | 2008-11-19 | — | — | EP | disclosed |
| WO-2008087529-A1 | NICOTINIC ACETYLCHOLINE RECEPTOR MODULATORS | SIENA BIOTECH S.P.A. (IT) | 2008-07-24 | — | — | WO | disclosed |
| WO-2007098826-A2 | MODULATORS OF ALPHA7 NICOTINIC ACETYLCHOLINE RECEPTORS AND THERAPEUTIC USES THEREOF | SIENA BIOTECH S.P.A. (IT) | 2007-09-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100029606-A1 | MODULATORS OF ALPHA7 NICOTINIC ACETYLCHOLINE RECEPTORS AND THERAPEUTIC USES THEREOF | CHRNA7, CHRNA2, CHRNA6 | RORC 244/4885KCNH2 1263/4885TUBB4A 1193/4885 |
| US-20100130474-A1 | ALPHA7 NICOTINIC ACETYLCHOLINE RECEPTOR INHIBITORS | CHRNA7, CHRNA6, CHRNA2 | RORC 316/4885KCNH2 909/4885TUBB4A 1651/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.